Oct 3 2012
The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month -- one-sixth of the $5,500 a month price charged by Bayer." According to the newspaper, "If Bayer loses the appeal, and the court upholds the compulsory license issued to Natco, a generics producer based in the central Indian city of Hyderabad, the precedent could encourage other Indian manufacturers to follow its lead by producing cheap generic versions of high-priced, patented drugs that are out of the reach of all but the wealthiest Indians."
"In another important case, India's Supreme Court this month began to hear final arguments in an appeal from Novartis of Switzerland, which has fought unsuccessfully since 2006 for a patent for its cancer treatment Glivec," the Financial Times notes. "But the Bayer case is causing the greatest concern, because it could encourage other generic producers to offer cut-price versions of drugs to overturn patents," the newspaper adds (Jack/Kazmin, 10/1).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Obesity crisis in the U.S. expected to worsen by 2050